Baxter and ScinoPharm sign injectable oncology drug strategic alliance

By Dan Stanton

- Last updated on GMT

Image: iStock/jarun011
Image: iStock/jarun011

Related tags Pharmacology Pharmaceutical drug

Up to 20 injectable cancer drugs will be made at facilities in Taiwan and Germany under terms of a partnership between Baxter and Scinopharm.

Baxter International and ScinoPharm Taiwan announced a strategic partnership yesterday to develop, manufacture and commercialise an initial five oncology drugs, with scope for an additional 15 injectable molecules.

“The collaboration with ScinoPharm represents a rare and compelling opportunity to partner with one of the world’s leading active pharmaceutical ingredient [API] manufacturers with a 17-year history of quality and safety serving the global pharmaceutical industry,”​ a spokesperson from Baxter told

Current branded sales of the initial five products included in this partnership total more than $4bn annually. Baxter is not disclosing specific cost details associated with this partnership.”


Manufacturing will be carried out at both Baxter’s facility in Halle, Germany and Scinopharm’s injectable plant in Tainan, Taiwan.

A Scinopharm spokesperson added the latter will be ready for registration batch production by 2017, with the first in-house ANDA submission from the partnership set for 2018, and a subsequent US FDA inspection approval expected in 2019.

“ScinoPharm will be responsible for raw material sourcing for all APIs and the injectables made in-house by ourselves,” ​Scinopharm told us. “Baxter will be responsible for raw material sourcing for the injectables made by themselves.”

Scinopharm invested NT$1.1bn ($36m) into its Tainan site in 2012​ to build a high potency cytotoxic injectable plant, and as such does not need to add new capacity or staff to service this collaboration, we were told.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more